Objective To observe the efficacy and safety of Pemetrexed plus cisplatin (DDP) for advanced nonsquamous non small cell lung cancer ( NSCLC). Methods Sixty-five patients with advanced nonsquamous NSCLC were divided into two groups. The therapy of Pemetrexed plus DDP was used in treatment group and Paclitaxel plus DDP was used in control group. The efficacy and adverse effects were observed after two courses of treatment Results The overall response rate (RR.) was 60. 00% in treatment group and 34. 29% in control group with significant difference between the two groups (x = 4. 298 ,P = 0.038). The main adverse effects in treatment group was fewer than that in control group (P < 0. 05). Conclusion Pemetrexed combined with DDP is effective and feasible for nonsquamous NSCLC,which is better tolerated by patients.%目的 观察培美曲塞(PEM)联合铂类治疗肺非小细胞非鳞癌的近期疗效和不良反应.方法 65例进展期非小细胞肺非鳞癌(ⅢB～Ⅳ期)患者中30例采用PEM联合顺铂(DDP)治疗(治疗组),35例采用紫杉醇联合DDP治疗(对照组),观察不良反应,治疗2个周期后评价疗效.结果 治疗组总有效率(RR)为60.00％,显著高于对照组(34.29％),差异有统计学意义(x2=4.298,P=0.038)；Ⅲ～Ⅳ级药物相关性血液学毒性也显著低于对照组(均P＜0.05)；4例脑转移患者病灶均有缩小,而对照组未见缩小.结论 PEM联合DDP治疗晚期非小细胞肺非鳞癌较紫杉醇联合DDP方案疗效更好,且有更好的耐受性.
展开▼
